Agenus and zydus lifesciences enter $141m strategic collaboration to advance bot/bal, expand zydus' biologics manufacturing in the us

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with zydus lifesciences ltd. (nse: zyduslife), including its subsidiaries/affiliates, hereafter referred to as “zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (bot/bal). the strategic collaboration includes an exchange of agenus' state-of-t.
AGEN Ratings Summary
AGEN Quant Ranking